Importantly, treatment with NRG4 and simultaneous blockage of ERBB2, which is expected to specifically trigger the activation of ERBB4-ERBB4 homodimers, restrained the growth of HER2+ breast cancer cells more efficiently than anti-HER2 drugs alone. The gene discussed is ERBB2; the disease is breast carcinoma.